NEUROGRAFT
Development of Functionalised Cell Seeded Bioartificial Organ for Transplantation in Nerve Repair
| Coordinatore | NATIONAL UNIVERSITY OF IRELAND, GALWAY
Organization address
address: University Road - contact info |
| Nazionalità Coordinatore | Ireland [IE] |
| Totale costo | 5˙534˙265 € |
| EC contributo | 4˙211˙374 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-2 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-12-01 - 2015-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
NATIONAL UNIVERSITY OF IRELAND, GALWAY
Organization address
address: University Road - contact info |
IE (GALWAY) | coordinator | 1˙320˙078.00 |
| 2 |
"Stemmatters, Biotecnologia e Medicina Regenerativa SA"
Organization address
city: BARCO GMR contact info |
PT (BARCO GMR) | participant | 1˙080˙475.74 |
| 3 |
Vornia Limited
Organization address
address: "UPPER NEWCASTLE ROAD, BUSINESS INNOVATION CENTRE, NATIONAL UNIVERSITY OF IRELAND GALWAY" contact info |
IE (GALWAY) | participant | 797˙383.60 |
| 4 |
BIOMATECH SAS
Organization address
address: Rue Pasteur - ZI de L'Islon contact info |
FR (CHASSE SUR RHONE) | participant | 513˙550.00 |
| 5 |
OBELIS SA
Organization address
address: BOULEVARD GENERAL WAHIS 53 contact info |
BE (BRUXELLES) | participant | 499˙887.50 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Injuries and degenerative diseases of the central nervous system constitute a bottleneck in medical and surgical practice for which no therapy currently exists. To ensure clinical translation, NeuroGraft is organised in three R&D Work-Packages. NeuroGraft will develop functionalised cell seeded bioartificial organs, specifically spinal cord conduits for transplantation, incorporating a potent immunomodulatory cytokine (IL37) to target the initial inflammatory response to increase the survival and therapeutic efficacy of transplanted mesenchymal cells and the expression of potent neuro-regulatory molecules for enhanced functional nerve regeneration in the central nervous system. This exciting concept will be realised through the NeuroGraft consortium, consisting of one academic and four industrial partners (all SMEs), across four countries, with distinct synergistic expertise (including regulatory expertise) to develop cell seeded functionalised bioartificial organs as valuable solutions towards spinal cord repair. Regulatory advice is incorporated at an early stage in the development cycle, to facilitate the translation of the novel bioartificial devices developed, to the market in as short a timeframe as possible. The NeuroGraft consortium will validate the safety, efficacy and biodistribution of the functionalised bioartificial organs developed in a pre-clinical model of spinal cord under GLP conditions. Full Quality Assurance reports will be completed towards CE Mark regulatory approval of the medical device for spinal cord repair. These studies will facilitate progression to clinical trials of the technology (post project) and the development of a marketable product within 6 years of the completion of the NeuroGraft project. Intellectual property will be patented ensuring that SME’s have veto rights on commercial route for exploitation. An extensive business plan outlining detailed valorisation plan is presented.'